News & Events

News

TriSalus Life Sciences to Present at the Society of Interventional Radiology’s 2022 Annual Scientific Meeting

*** MEDIA ADVISORY ***

BOSTON, June 6, 2022TriSalus Life Sciences®, an interventional immunotherapy company on a mission to extend and improve the lives of patients with liver and pancreatic tumors, will present a series of events at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting, held June 11-16, 2022, at the Boston Convention and Exhibition Center.

 

The TriSalus™ clinical leadership team will be on-site to discuss the company’s FDA-cleared TriNav® Infusion System as well as ongoing research with the interventional radiology (IR) community, including two presentations on new pre-clinical data that inform the company’s immunotherapeutic platform approach.

 

The company is pioneering an integrated platform approach that aims to overcome immunosuppression and delivery barriers by combining an investigational toll-like receptor 9 agonist, SD-101, with innovative drug delivery technology. The TriNav® Infusion System utilizes the Pressure-Enabled Drug Delivery™ (PEDD™) method of administration with SmartValve™ to overcome intratumoral pressure and improve delivery of therapeutic agents during outpatient interventional radiology procedures.

 

Additional activities, including a Monday evening reception, are highlighted below.

 

ON-SITE TRISALUS SPOKESPERSONS

Steven C. Katz, MD, FACS, Chief Medical Officer

David B. Jaroch, PhD, Senior Principal Scientist

Alexander Y. Kim, MD, Director of Interventional Oncology Clinical Strategies

Mikael Trollsas, PhD, Senior Vice President of Research and Development

 

CONFERENCE ACTIVITIES

 

Sunday, June 12 – Tuesday, June 14

TriNav Exhibition, Booth #605

Visit Booth #605 to see a replica of the TriNav® Infusion System and learn how the device is engineered to improve tumor response, increase therapeutic delivery, and target tumors more precisely.

 

Sunday, June 12

Hands-on Workshop, Interventional Oncology: Embolization, 3:00 – 4:30pm ET, Exhibit Hall C

During this interactive workshop, attendees can experience what makes the TriNav® Infusion System different from standard delivery approaches.

 

Monday, June 13

Taste of New England: An Evening Reception, Presented by TriSalus Life Sciences, 6:30-8:00pm ET

Westin Boston Seaport – Marina Ballroom II

Join the TriSalus™ team for an evening networking and education reception, complete with New England favorites. (Media RSVP for the event by emailing press@trisaluslifesci.com.)

 

Wednesday, June 15

(Scientific Sessions listed below are part of the SIR 2022 CME-accredited scientific program and not a TriSalus-sponsored activity.)

Scientific Session: IO Frontiers 2, 3:18-3:27pm ET, Room 253B

Abstract Title: Improved Delivery of a TLR-9 Agonist to Liver Tissue by Intravascular Pressure Enabled Drug Delivery (PEDD) Compared with Direct Needle Injection

Hear TriSalus™ Senior Principal Scientist David B. Jaroch, PhD highlight promising results from a pre-clinical study comparing local injection of labeled SD-101 into hepatic tissue versus using the PEDD™ method. 

 

Scientific Session: Venous Disease and Sampling, 4:21-4:30pm ET, Room 258A

Abstract Title: Comparison of Pancreatic Tissue Uptake of Oxaliplatin Delivered by Systemic Circulation and by Pancreatic Retrograde Venous Infusion (PRVI)

TriSalus™ Senior Principal Scientist David B. Jaroch, PhD will present on the development of a trans-venous approach for regional treatment of pancreatic tumors, using a catheter capable of modulating pressure and flow within the organ to promote drug uptake.

 

###

About TriSalus Life Sciences
TriSalus Life Sciences is an immunotherapy company on a mission to extend and improve the lives of patients living with liver and pancreatic tumors. By integrating an immunotherapeutic with innovative drug delivery technologies, TriSalus’ platform seeks to address two of the most significant barriers that limit the effectiveness of current treatments for liver and pancreatic tumors: immunosuppression and high intratumoral pressure.

 

The company is studying the ability of SD-101, a potentially first-in-class, investigative TLR9 agonist, to reactivate the immune system within the liver and pancreas to enable more durable responses to other immunotherapeutics (e.g., checkpoint inhibitors) and improve patient outcomes. The platform, which leverages TriSalus’ proprietary Pressure-Enabled Drug Delivery™ (PEDD™) method of administration, modulates pressure and flow within blood vessels to improve the amount of therapy delivered to the tumor. While meaningful progress in these difficult-to-treat diseases will not be easy, TriSalus is focused on advancing science and technological innovation to transform outcomes for patients. To learn more, visit www.trisaluslifesci.com and follow us on Twitter @TriSalusLifeSci and LinkedIn.